Tamoxifen in early breast cancer.
T
T
Saibara
Y
Y
Ogawa
S
S
Onishi
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015415:Biomarkers / Q000032:analysis; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018955:CD36 Antigens / Q000032:analysis; D004965:Estrogen Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005234:Fatty Liver / Q000139:chemically induced / Q000473:pathology; D005260:Female; D005434:Flow Cytometry; D016650:Fluorescein-5-isothiocyanate; D005456:Fluorescent Dyes; D006801:Humans; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D015415:Biomarkers; D018955:CD36 Antigens; D004965:Estrogen Antagonists; D005456:Fluorescent Dyes; D013629:Tamoxifen; D016650:Fluorescein-5-isothiocyanate